Full year report 2012 - Nobel Biocare Corporate

More documents

Recommendations

Info

Income statementin EUR ‘000 Note Q4 2012 Q4 2011 FY 2012 FY 2011Revenue 6 152’994 154’621 580’485 569’179Cost of goods sold –38’255 –37’406 –143’003 –136’677Gross profit 114’739 117’215 437’482 432’502Selling and marketing expenses 1 –69’557 –66’066 –259’536 –252’219Administrative expenses 1 –20’518 –20’077 –74’252 –79’152Research and development expenses –10’346 –8’028 –35’008 –29’005Profit from operations (EBIT) 14’318 23’044 68’686 72’126Financial income 7 683 414 1’207 2’335Finance cost 7 –2’338 –3’882 –9’076 –14’318Net foreign exchange result 7 1’123 –883 178 –4’674Profit before tax 13’786 18’693 60’995 55’469Income tax expenses –2’636 –5’428 –15’146 –15’688Profit attributable to owners of Nobel Biocare 11’150 13’265 45’849 39’781Basic earnings per share (EUR) 0.09 0.11 0.37 0.32Diluted earnings per share (EUR) 0.09 0.11 0.37 0.321 Certain comparatives have been reclassified from administrative to selling and marketing expenses.Statement of comprehensive incomein EUR ‘000 Note Q4 2012 Q4 2011 FY 2012 FY 2011Profit attributable to owners of Nobel Biocare 11’150 13’266 45’849 39’781Other comprehensive income:Foreign currency translation differences –4’916 17’913 523 –37’276Effective portion of changes in fair valueof net investment hedges 867 – –633 –Reclassification of foreign currency translationdifferences to income statement, net of tax 7 – 508 – 1’217Effective portion of changes in fair valueof cash flow hedges, net of tax 1’158 –257 3’474 –6’397Net change in fair value of cash flow hedgesreclassified to income statement, net of tax 7 –490 109 1’315 –2’649Total other comprehensive income/(expenses)for the period, net of tax –3’381 18’273 4’679 –45’105Total comprehensive income/(expenses) for theperiod attributable to owners of Nobel Biocare 7’769 31’539 50’528 –5’324Full year report 201212/21
Balance sheetin EUR ‘000 Note 31 December 2012 31 December 2011AssetsProperty, plant and equipment 70’950 86’331Intangible assets 205’674 212’558Non-current receivables 3’940 3’420Deferred tax assets 17’274 22’235Total non-current assets 297’838 324’544Inventories 20’433 23’946Trade and other receivables 96’217 109’362Current income tax assets 17’411 5’799Prepaid expenses and accrued income 13’743 13’754Derivative financial instruments 8’369 7’389Cash and cash equivalents 1 146’571 107’456Total current assets 302’744 267’706Total assets 600’582 592’250Equity and liabilitiesShare capital 8 31’861 31’861Share premium 108’547 111’023Treasury shares –16’185 –21’498Retained earnings 200’825 160’118Total equity attributable to owners of Nobel Biocare 325’048 281’504Provisions 3’134 3’172Pension liabilities 10’353 8’643Loans and borrowings 99’505 98’400Deferred tax liabilities 27’324 26’269Other non-current liabilities 244 357Total non-current liabilities 140’560 136’841Loans and borrowings – 36’928Trade payables 19’191 15’378Current provisions 8’763 5’935Current income tax liabilities 38’941 36’763Other current liabilities and derivatives 11’443 16’748Accrued expenses and deferred income 56’636 62’153Total current liabilities 134’974 173’905Total liabilities 275’534 310’746Total equity and liabilities 600’582 592’2501 As of 31 December 2012, the Group held no restricted cash (31 December 2011: EUR 7’122 k).Full year report 201213/21
Page 1 and 2: Media ReleaseFull year report 2012Z
Page 3 and 4: Alpha-Bio Tec (ABT) is targeting cu
Page 5 and 6: OsseoCare TM Pro, that was introduc
Page 7 and 8: The complete Full Year Report 2012
Page 9 and 10: Selected financial informationin EU
Page 11: Condensed consolidatedfinancial sta
Page 15 and 16: Cash flow statementin EUR ‘000 No
Page 17 and 18: Operating segments are identified g
Page 19 and 20: The share capital may be increased
Page 21: In June 2010, a Canadian company fi

Full year report 2012 - Nobel Biocare Corporate

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?